Tolerability of indacaterol, a novel once-daily beta 2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.
William H. Yang et all. Annals of Allergy, Asthma and Immunology, 01/2008.
Indacaterol, a new once-daily beta 2-agonist for asthma treatment, was tolerated well in one-month study.
Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. Annals of Allergy, Asthma and Immunology, 01/2008.
Daniel L. Hamilos et al.
Few studies have explored the safety of long term use of racemic albuterol, and none have examined long-term dosing of levalbuterol. In this trial, regular use of levalbuterol HFA MDI or racemic albuterol HFA MDI was well tolerated, and no deterioration of lung function was detected during the study period of 52 weeks (1 year).
Image source: Wikipedia, public domain.